264 related articles for article (PubMed ID: 11952857)
1. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
2. Hybrid thyroid carcinoma with a coarse chromatin pattern and nuclear features of papillary thyroid carcinoma.
Mai KT; Bokhary R; Yazdi HM; Thomas J
Pathol Res Pract; 2002; 198(4):253-60. PubMed ID: 12049333
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
4. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
Guyétant S; Michalak S; Valo I; Saint-André JP
Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
[TBL] [Abstract][Full Text] [Related]
7. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors.
Judkins AR; Roberts SA; Livolsi VA
Hum Pathol; 1999 Nov; 30(11):1373-6. PubMed ID: 10571520
[TBL] [Abstract][Full Text] [Related]
8. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
9. Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
Mai KT; Elmontaser G; Perkins DG; Thomas J; Stinson WA
Int J Surg Pathol; 2005 Jan; 13(1):37-41. PubMed ID: 15735853
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
12. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
13. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
Choi YL; Kim MK; Suh JW; Han J; Kim JH; Yang JH; Nam SJ
J Korean Med Sci; 2005 Oct; 20(5):853-9. PubMed ID: 16224162
[TBL] [Abstract][Full Text] [Related]
14. Fine-needle aspirations of papillary carcinoma with oncocytic features: an expanded cytologic and histologic profile.
Renshaw AA
Cancer Cytopathol; 2011 Aug; 119(4):247-53. PubMed ID: 21400667
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.
Troncone G; Iaccarino A; Russo M; Palmieri EA; Volante M; Papotti M; Viglietto G; Palombini L
J Clin Pathol; 2007 Apr; 60(4):377-81. PubMed ID: 16798934
[TBL] [Abstract][Full Text] [Related]
16. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
[TBL] [Abstract][Full Text] [Related]
17. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
18. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
[TBL] [Abstract][Full Text] [Related]
20. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.
Miettinen M; Kärkkäinen P
Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
